STOCK TITAN
The best stock market news and trading tools all in one place—your must-have platform for investing success.
A must-have platform for stock market information, offering the best tools and updates to supercharge your trading.
Your trusted source for the best stock market news, trading tools, and expert advice. Everything traders need, in one place.

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Accelerate Diagnostics (NASDAQ: AXDX) will participate in the William Blair 41st Annual Growth Stock Conference on June 3, 2021, at 12:00 p.m. Central Time. CEO Jack Phillips and CFO Steve Reichling will present virtually, and a live audiocast will be available on the company's investor relations website. The company specializes in in vitro diagnostics, focusing on solutions for antibiotic resistance and sepsis, with its Accelerate Pheno® system providing faster results for antibiotic susceptibility testing.

Positive
  • None.
Negative
  • None.

TUCSON, Ariz., May 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m. Central Time.

A live audiocast of the session will be accessible through the company's investor relations website at ir.axdx.com. A replay of the audiocast will be available for at least 30 days following the conference.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for serious infections. The FDA-cleared system and kit fully automate sample preparation steps, enabling phenotypic antibiotic susceptibility results in about 7 hours directly from positive blood cultures. Recent external studies indicate the solution offers results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-to-participate-in-william-blair-41st-annual-growth-stock-conference-on-june-3-2021-301294554.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When will Accelerate Diagnostics present at the William Blair conference?

Accelerate Diagnostics will present on June 3, 2021, at 12:00 p.m. Central Time.

Who will represent Accelerate Diagnostics at the conference?

CEO Jack Phillips and CFO Steve Reichling will represent Accelerate Diagnostics.

Where can I listen to the audiocast of the Accelerate Diagnostics presentation?

The audiocast will be available on the company's investor relations website at ir.axdx.com.

How does the Accelerate Pheno® system help clinicians?

The Accelerate Pheno® system reduces the time needed to determine optimal antibiotic therapy, providing results in about 7 hours.

What is the significance of the Accelerate PhenoTest® BC kit?

The Accelerate PhenoTest® BC kit enables phenotypic antibiotic susceptibility results 1 to 2 days faster than traditional methods.

Accelerate Diagnostics, Inc.

NASDAQ:AXDX

AXDX Rankings

AXDX Latest News

AXDX Stock Data

40.32M
15.42M
40.61%
17.45%
2%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
TUCSON